Aventis Pharmaceutical agreed to pay $95.5 million to settle allegations it violated the False Claims Act by misreporting drug prices, the Dept. of Justice announced on May 28.

The government said Aventis manipulated its “best price” numbers for nasal sprays by entering into an agreement with the HMO Kaiser Permanente that repackaged Aventis’ drugs under a new label. The agreement allowed Aventis to avoid paying millions of dollars in rebates to Medicaid programs, the department said.

Let us help you.
Get a free, confidential case review